Navigation Links
Stereotaxis Appoints Senior Vice President, North America
Date:6/20/2008

St. John's University.

About Stereotaxis

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Stereotaxis System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure. The core components of the Stereotaxis system have received regulatory clearance in the U.S., Europe and Canada.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance for the Company's products in the marketplace, competitive factors, changes in government reimbursement procedures, dependence upon third-party vendors, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to continge
'/>"/>

SOURCE Stereotaxis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Stereotaxis Niobe System Used to Perform More Than 10,000 Procedures Worldwide
2. Stereotaxis Announces FDA Approval of Its Partnered Magnetic Irrigated Catheter
3. Stereotaxis Appoints David Burkhardt, M.D. as Chief Medical Officer
4. Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results
5. Stereotaxis Highlights a Transatlantic Arrhythmia Procedure Collaboration With the Odyssey(TM) Network
6. Stereotaxis Market Leadership Highlighted at Heart Rhythm 2008
7. Stereotaxis to Present at the Seventh Annual JMP Securities Research Conference
8. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
9. Codexis Appoints Singapore Laboratories Managing Director
10. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... WARREN, N.J. , April 30, 2015  Roka ... company focused on providing advanced testing solutions for the ... financial results for the first quarter of 2015 on ... markets. Roka Bioscience will also host a ... 7, 2015 to discuss its first quarter financial results. ...
(Date:4/30/2015)... Nitto Avecia, a leading biotechnology manufacturer ... and production capability to serve biotechnology pharmaceutical clients. ... fulfillment continues to drive Nitto Avecia to enhance ... , In Fall 2014, Nitto Avecia ... at its Milford, MA facility, which is recognized ...
(Date:4/30/2015)... April 30, 2015  The Paul G. Allen Family ... (ADI) grants to six groups of researchers with projects ... roadblocks in neuroscience: growing mature human brain cells in ... of $7.5 million over three years.  ... research is especially significant because the field of neuronal ...
(Date:4/30/2015)... WuXi PharmaTech (Cayman) Inc. ("WuXi" or the "Company") (NYSE: ... provider, today announced that its board of directors has ... 2015, from a consortium (the "Consortium") led by Dr. ... chief executive officer of the Company, and Ally Bridge ... "Transaction") involving the acquisition of all outstanding shares of ...
Breaking Biology Technology:Roka Bioscience to Report First Quarter 2015 Financial Results On May 7, 2015 2Biotechnology Manufacturer Nitto Avecia Expands Capacity to Meet Client Demand 2The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 2The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 3The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 4The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 5WuXi PharmaTech Announces Receipt of Proposal 2WuXi PharmaTech Announces Receipt of Proposal 3WuXi PharmaTech Announces Receipt of Proposal 4WuXi PharmaTech Announces Receipt of Proposal 5WuXi PharmaTech Announces Receipt of Proposal 6
... SOUTH SAN FRANCISCO, Calif., Jan. 12 Sunesis Pharmaceuticals, ... clinical update on voreloxin, its novel investigational drug candidate ... myeloid leukemia (AML) and ovarian cancer. The clinical ... Annual JP Morgan Healthcare Conference in San Francisco. "2008 ...
... Calif., Jan. 12 MAP,Pharmaceuticals, Inc. (Nasdaq: ... 3 clinical programs, Unit Dose Budesonide (UDB) for children,with ... For UDB, all,patients have completed the 12 week ... for MAP0004, the company currently expects to complete,enrollment in ...
... Calif., Jan. 12 Anacor Pharmaceuticals today,announced that it ... million from its collaboration partner, GlaxoSmithKline. Anacor may,receive ... to clinical development and commercial sales. , ... we have made as a result of,the alliance we ...
Cached Biology Technology:Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin 2Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin 3Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin 4Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin 5Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin 6MAP Pharmaceuticals Provides Update on Progress of Two Phase 3 Clinical Programs 2MAP Pharmaceuticals Provides Update on Progress of Two Phase 3 Clinical Programs 3Anacor Achieves Milestone from GSK for Boron-Based Systemic Antibacterial Product Candidate 2
(Date:4/14/2015)... Conn. , April 14, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... been nominated for the 2015 New York Design Awards ... The Design100, New York City Design Awards are part ... based on over 2,500 ratings from the marketplace, industry ...
(Date:4/13/2015)...  higi, a leading cloud-based consumer engagement platform that ... with their communities around health and wellness, announced today ... API.  ... and convenient vehicle to receive validated health information from ... The API will allow higi,s trusted partners, on a ...
(Date:4/9/2015)... SAN JOSE, Calif. , April 9, 2015 /PRNewswire/ ... of human interface solutions, announced today that it will ... 2015 on Thursday, April 23, 2015, after the close ... call for analysts and investors at 2:00 p.m. PT ... information.    To participate on the live ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3Synaptics to Report Third Quarter Results on April 23 2
... The first real-world, demonstration-scale project in Nevada for ... stage of research at the University of Nevada, Reno. ... is an economical, commercially viable renewable energy source in ... outdoor cold-weather crop of algae as part of their ...
... TGen Clinical Research Services (TCRS) at Scottsdale Healthcare ... may offer broad potential to treat solid tumors. ... conducted at TGen Clinical Research Services at Scottsdale Healthcare, ... (TGen) and Scottsdale-based Scottsdale Healthcare Corp., and at Mayo ...
... bleaching is not only a con, but is dangerous to ... journal. The light treatment gives absolutely no benefit over ... four times as much as sunbathing, reports a study in ... match Tom Cruise,s glittering pearly-whites would be better off ignoring ...
Cached Biology News:Success for first outdoor, large-scale algae-to-biofuel research project in Nevada 2TGen Clinical Research Services at Scottsdale Healthcare and Mayo Clinic study new cancer drug 2
... Continuing a tradition of progressive centrifuge design ... series. The Centra-CL3 and Centra-CL3R (refrigerated) general ... laboratory., Quality Control Over Sample Preparation ... lock up to 99 protocols and has ...
... Molecular Probes intensely fluorescent and ... potential for use in a variety ... deliver a strong signal. Unfortunately, protein- ... regions that may cause them to ...
... Centra-CL5R multi-purpose centrifuge offers both high-speed ... assortment of rotor options, making it ... applications., Maximum Versatility , High-speed ... angle rotors or high-volume (4 x 250mL) ...
... licensed, high throughput, water bath thermal cycler capable ... microplates. This equates to 9,216 reactions per run ... rapidly transfers a basket of plates between three ... are considerably faster than those of peltier block ...
Biology Products: